S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
What is a Gold IRA, and is it a Viable Investment?
The "King Of Quants" sees 10X potential... (Ad)
Closing prices for crude oil, gold and other commodities
UN body mulls deep sea mining amid demand for minerals
The "King Of Quants" sees 10X potential... (Ad)
MarketBeat Week in Review – 3/27 - 3/31
Canada approves largest telecom deal in country's history
Biden's corruption knows no end (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
Medicare, Social Security could fall short over next decade
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
What is a Gold IRA, and is it a Viable Investment?
The "King Of Quants" sees 10X potential... (Ad)
Closing prices for crude oil, gold and other commodities
UN body mulls deep sea mining amid demand for minerals
The "King Of Quants" sees 10X potential... (Ad)
MarketBeat Week in Review – 3/27 - 3/31
Canada approves largest telecom deal in country's history
Biden's corruption knows no end (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
Medicare, Social Security could fall short over next decade
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
What is a Gold IRA, and is it a Viable Investment?
The "King Of Quants" sees 10X potential... (Ad)
Closing prices for crude oil, gold and other commodities
UN body mulls deep sea mining amid demand for minerals
The "King Of Quants" sees 10X potential... (Ad)
MarketBeat Week in Review – 3/27 - 3/31
Canada approves largest telecom deal in country's history
Biden's corruption knows no end (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
Medicare, Social Security could fall short over next decade
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
What is a Gold IRA, and is it a Viable Investment?
The "King Of Quants" sees 10X potential... (Ad)
Closing prices for crude oil, gold and other commodities
UN body mulls deep sea mining amid demand for minerals
The "King Of Quants" sees 10X potential... (Ad)
MarketBeat Week in Review – 3/27 - 3/31
Canada approves largest telecom deal in country's history
Biden's corruption knows no end (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
Medicare, Social Security could fall short over next decade
NASDAQ:CRSP

CRISPR Therapeutics - CRSP Stock Forecast, Price & News

$45.23
+1.07 (+2.42%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$44.07
$45.69
50-Day Range
$43.14
$56.12
52-Week Range
$38.94
$86.95
Volume
1.18 million shs
Average Volume
953,601 shs
Market Capitalization
$3.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$72.89

CRISPR Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
61.2% Upside
$72.89 Price Target
Short Interest
Bearish
16.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.98mentions of CRISPR Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$3.60 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($7.35) to ($5.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

460th out of 1,004 stocks

Biological Products, Except Diagnostic Industry

80th out of 166 stocks


CRSP stock logo

About CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Receive CRSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRSP Stock News Headlines

5 Stocks to Buy Immediately
America’s #1 stock picker issues 5 buy alerts – one of which is positioned to be the next Tesla. Just click to claim your copy. pixel
5 Stocks to Buy Immediately
America’s #1 stock picker issues 5 buy alerts – one of which is positioned to be the next Tesla. Just click to claim your copy. pixel
Intellia's (NTLA) HAE Therapy Granted RMAT by the FDA
Ready to Buy the Dip? Consider This Gene Editing Stock
See More Headlines
Receive CRSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRSP Company Calendar

Last Earnings
2/21/2023
Today
4/01/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRSP
Fax
N/A
Employees
473
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$72.89
High Stock Price Forecast
$123.00
Low Stock Price Forecast
$39.00
Forecasted Upside/Downside
+61.2%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
18 Analysts

Profitability

Net Income
$-650,170,000.00
Net Margins
-54,271.70%
Pretax Margin
-54,298.84%

Debt

Sales & Book Value

Annual Sales
$1.20 million
Book Value
$23.95 per share

Miscellaneous

Free Float
74,479,000
Market Cap
$3.56 billion
Optionable
Optionable
Beta
1.73

Key Executives

  • Dr. Rodger Novak M.D. (Age 55)
    Founder, Chairman & Pres
  • Dr. Samarth  KulkarniDr. Samarth Kulkarni (Age 43)
    CEO & Director
    Comp: $1.18M
  • Dr. Lawrence Otto Klein Ph.D. (Age 40)
    Chief Operating Officer
    Comp: $675k
  • Mr. James R. KasingerMr. James R. Kasinger (Age 50)
    Gen. Counsel & Sec.
    Comp: $648.93k
  • Mr. Shaun Foy
    Founder
  • Dr. Emmanuelle Marie Charpentier
    Co-Founder & Scientific Advisory Board Member
  • Dr. Craig C. Mello Ph.D.
    Scientific Founder & Advisory Board Member
  • Dr. Chad Cowan Ph.D.
    Scientific Founder
  • Dr. Matthew Porteus M.D. (Age 56)
    Ph.D., Scientific Founder & Advisory Board Member
  • Dr. Daniel G. Anderson Ph.D.
    Scientific Founder & Advisory Board Member













CRSP Stock - Frequently Asked Questions

Should I buy or sell CRISPR Therapeutics stock right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CRSP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRSP, but not buy additional shares or sell existing shares.
View CRSP analyst ratings
or view top-rated stocks.

What is CRISPR Therapeutics' stock price forecast for 2023?

18 brokerages have issued 12 month price targets for CRISPR Therapeutics' stock. Their CRSP share price forecasts range from $39.00 to $123.00. On average, they expect the company's stock price to reach $72.89 in the next year. This suggests a possible upside of 61.2% from the stock's current price.
View analysts price targets for CRSP
or view top-rated stocks among Wall Street analysts.

How have CRSP shares performed in 2023?

CRISPR Therapeutics' stock was trading at $40.65 at the beginning of the year. Since then, CRSP stock has increased by 11.3% and is now trading at $45.23.
View the best growth stocks for 2023 here
.

When is CRISPR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our CRSP earnings forecast
.

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) announced its earnings results on Tuesday, February, 21st. The company reported ($1.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.27) by $0.86. The company had revenue of $6 million for the quarter, compared to the consensus estimate of $7.37 million. CRISPR Therapeutics had a negative trailing twelve-month return on equity of 31.85% and a negative net margin of 54,271.70%. The firm's revenue for the quarter was down 53.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.84) EPS.

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $45.23.

How much money does CRISPR Therapeutics make?

CRISPR Therapeutics (NASDAQ:CRSP) has a market capitalization of $3.56 billion and generates $1.20 million in revenue each year. The company earns $-650,170,000.00 in net income (profit) each year or ($8.37) on an earnings per share basis.

How many employees does CRISPR Therapeutics have?

The company employs 473 workers across the globe.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The official website for the company is www.crisprtx.com. The company can be reached via phone at (141) 561-3277 or via email at susan.kim@crisprtx.com.

This page (NASDAQ:CRSP) was last updated on 4/1/2023 by MarketBeat.com Staff